FOLD - Comprehensive Filing Intelligence

FY 2025•10-K•Filed Feb 20, 2026

5.0/10

Filing Health:CAUTION

Notable concerns that warrant closer review

Executive Summary

Liquidity appears sufficient for the next 12 months, but long-term funding needs are subject to numerous uncertainties and the outcome of the BioMarin transaction.. Net product sales increased by $105.9 million driven by Galafold and Pombiliti + Opfolda growth and favorable FX.

Top Concerns

!In 2025 and 2024, one customer accounted for % and % of net product sales, respectively. As of December 31, 2025, two customers each accounted for %, respectively, of account receivables from product....
!The company reported negative net income in 2025, which, combined with a very low gross margin (0.9%), raises concerns about the sustainability of operations without further funding.
!Pending Transaction with BioMarin (high)
!Supply Chain Disruption due to Geopolitical Tensions (high)

Top Positives

+The company is focused on developing and commercializing rare disease therapies, with Galafold® and Pombiliti® + Opfolda® showing continued growth.
+Significant R&D investment, including a new license for DMX-200, and increased SG&A due to litigation and a pending merger with BioMarin are impacting profitability.
+Operating cash flow turned positive in 2025, supported by working capital adjustments, primarily a substantial inventory build-up.

Analysis Dimensions

Our 5-pass AI analysis examines this filing across multiple dimensions. Each dimension score is derived from direct analysis of SEC filing text.

Narrative Intelligence

6.0/10

Management tone is balanced with focus on increase in net product sales of galafold® and pombiliti® + opfolda®.

Full analysis includes: tone changes vs prior quarter, margin driver breakdown, forward guidance analysis, strategic priorities.

Accounting Quality

6.0/10

Earnings quality shows moderate accounting practices.

Full analysis includes: reserve and allowance changes, non-recurring item analysis, stock-based compensation impact, disclosure concerns.

Hidden Liabilities

Off-balance sheet risk is low.

Full analysis includes: cloud and purchase commitments, VIE/SPE exposure, covenant compliance status, refinancing risk assessment.

Risk Landscape

2.0/10

Overall risk profile shows pending transaction with biomarin as primary concern.

Full analysis includes: 8 risk categories with severity, new vs escalated risks, management response assessment, risk trend analysis.

Segment Performance

5.0/10

Segment health analysis.

Full analysis includes: segment-by-segment revenue breakdown, geographic concentration risk, customer concentration analysis, segment margin trends.